Document is current
Any future updates will be listed below
-
Authors
Addinsell, Hasse M.
Cant, Rachel https://orcid.org/0000-0003-0831-0452
Hull, Nathan J. https://orcid.org/0000-0001-8494-9261
Wang, Yu-Hung
Somervaille, Tim C. P. https://orcid.org/0000-0002-9188-4379
Wiseman, Daniel H. https://orcid.org/0000-0003-0715-1402
Batta, Kiran https://orcid.org/0000-0002-3494-0979
-
Funding
Funding for this research was provided by:
Oglesby Charitable Trust
Pickering Family Charitable Trust
Leukemia and Lymphoma Society, USA
Cancer Research UK (C5759/A20971)
- License Information
-
More Information
Article History
Received: 7 August 2024
Revised: 12 December 2024
Accepted: 27 December 2024
First Online: 15 January 2025
Competing interests
: The authors declare no competing interests.
: PBMNC samples were obtained from CMML patients treated at The Christie NHS Foundation Trust (Manchester, UK) recruited to the Manchester Cancer Research Centre Tissue Biobank (initiated with the approval of South Manchester Research Ethics Committee). PBMNCs from age-matched Healthy volunteers were used as controls. All patients and controls gave informed consent according to the Declaration of Helsinki. The study was approved by the UK Health Research Authority (REC: 19/LO/0564).
